EGRX Stock - Eagle Pharmaceuticals, Inc.
Unlock GoAI Insights for EGRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $316.61M | $171.55M | $187.80M | $195.89M | $213.31M |
| Gross Profit | $221.67M | $129.37M | $142.34M | $135.00M | $151.40M |
| Gross Margin | 70.0% | 75.4% | 75.8% | 68.9% | 71.0% |
| Operating Income | $80.96M | $2.77M | $32.95M | $21.82M | $36.62M |
| Net Income | $35.64M | $-8,627,000 | $11.99M | $14.31M | $31.90M |
| Net Margin | 11.3% | -5.0% | 6.4% | 7.3% | 15.0% |
| EPS | $2.76 | $-0.66 | $0.89 | $1.04 | $2.16 |
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 10th 2023 | Piper Sandler | Downgrade | Underweight | $17← $26 |
| August 9th 2023 | Piper Sandler | Downgrade | Underweight | $17← $26 |
Earnings History & Surprises
EGRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Nov 13, 2024 | — | — | — | — |
Q3 2024 | Aug 26, 2024 | $0.77 | — | — | — |
Q2 2024 | May 22, 2024 | $0.98 | — | — | — |
Q1 2024 | Mar 28, 2024 | $1.07 | — | — | — |
Q4 2023 | Nov 9, 2023 | $1.09 | $-0.27 | -124.8% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $1.05 | $1.18 | +12.4% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $1.19 | $1.26 | +5.9% | ✓ BEAT |
Q1 2023 | Mar 13, 2023 | $0.78 | $1.10 | +41.0% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $0.84 | $1.12 | +33.3% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $3.13 | $1.56 | -50.2% | ✗ MISS |
Q2 2022 | May 9, 2022 | $3.88 | $4.04 | +4.1% | ✓ BEAT |
Q1 2022 | Mar 7, 2022 | $0.87 | $0.85 | -2.3% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $0.87 | $0.56 | -35.6% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $0.88 | $0.93 | +5.7% | ✓ BEAT |
Q2 2021 | May 10, 2021 | $0.72 | $0.24 | -66.7% | ✗ MISS |
Q1 2021 | Mar 2, 2021 | $-0.43 | $0.96 | +323.3% | ✓ BEAT |
Q4 2020 | Nov 2, 2020 | $0.29 | $1.17 | +303.4% | ✓ BEAT |
Q3 2020 | Aug 10, 2020 | $0.14 | $0.57 | +307.1% | ✓ BEAT |
Q2 2020 | May 11, 2020 | $0.47 | $0.84 | +78.7% | ✓ BEAT |
Q1 2020 | Mar 2, 2020 | $0.35 | $0.48 | +37.1% | ✓ BEAT |
Latest News
Frequently Asked Questions about EGRX
What is EGRX's current stock price?
What is the analyst price target for EGRX?
What sector is Eagle Pharmaceuticals, Inc. in?
What is EGRX's market cap?
Does EGRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to EGRX for comparison